Formycon AG (ETR:FYB)

Market Cap	360.53M -8.1%
Revenue (ttm)	61.24M +18.3%
Net Income	-25.13M
EPS	-1.42
Shares Out	17.67M
PE Ratio	n/a
Forward PE	82.93
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,655
Open	20.40
Previous Close	20.40
Day's Range	19.90 - 20.75
52-Week Range	15.80 - 26.95
Beta	0.72
Analysts	Strong Buy
Price Target	39.67 (+99.35%)
Earnings Date	Nov 12, 2026

About Formycon AG

Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well as AHZANTIVE, Baiama, and Fovlya brand names. The company’s pipeline includes ustekinumab used in the treatment of Crohn’s disease, ulcerative colitis...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 196
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: FYB

Financial Performance

In 2025, Formycon AG's revenue was 44.48 million, a decrease of -36.17% compared to the previous year's 69.67 million. Losses were -64.70 million, -48.52% less than in 2024.

Analyst Summary

According to 7 analysts, the average rating for FYB stock is "Strong Buy." The 12-month stock price target is €39.67, which is an increase of 99.35% from the latest price.

Price Target

€39.67

(99.35% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 16, 2026

Data Sources Report a data error